prikaz prve stranice dokumenta Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi
  Download
PDF 300.05 KB
master's thesis
Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi
2016. urn:nbn:hr:171:628751
Tomić, Zdenko
University of Split
School of Medicine
Internal medicine

Cite this document

Tomić, Z. (2016). Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:628751

Tomić, Zdenko. "Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi." Master's thesis, University of Split, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:171:628751

Tomić, Zdenko. "Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi." Master's thesis, University of Split, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:171:628751

Tomić, Z. (2016). 'Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi', Master's thesis, University of Split, School of Medicine, accessed 12 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:628751

Tomić Z. Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi [Master's thesis]. Split: University of Split, School of Medicine; 2016 [cited 2024 November 12] Available at: https://urn.nsk.hr/urn:nbn:hr:171:628751

Z. Tomić, "Preživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi", Master's thesis, University of Split, School of Medicine, Split, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:171:628751

Please login to the repository to save this object to your list.
Metadata
TitlePreživljenje bolesnika s mišićnoneinvazivnim rakom mokraćnog mjehura liječenih intravezikalnom primjenom Bacillus Calmette-Guerin prema SWOG i reduciranoj SWOG shemi
Title (english)Survival rates of patients with non-muscle invasive bladder cancer treated with intravesical application of Bacillus Calmette-Guerin therapy according to SWOG and reduced SWOG scheme
AuthorZdenko Tomić
MentorMarijan Šitum (mentor)
GranterUniversity of Split
School of Medicine
(Internal medicine)
Split
Defense date and country2016, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Urology
Abstract
Cilj istraživanja: Cilj ovog istraživanja bio je pokazati učinkovitost reducirane SWOG (Southwest Oncology Group) sheme u postizanju jednakih stopa općeg i tumor-specifičnog preživljenja kao kod standardizirane SWOG terapijske sheme. Ispitanici i postupci: Proveli smo povijesno prospektivno istraživanje dugog praćenja. Podatci o pacijentima dobiveni su uvidom u operacijske protokole, patohistološke nalaze reseciranog tumorskog tkiva te praćenjem pacijenata do smrti ili zadnje kontrole. Mjesto istraživanja bilo na Zavodu za urologiju KBC-a Split. U istraživanje je uključeno 99 bolesnika koji su u razdoblju od 1. siječnja 2004. do 31. prosinca 2007. liječeni od mišićnoneinvazivnih karcinoma mokraćnog mjehura transuretralnom resekcijom te dodatnom intravezikalnom instilacijom BCG prema SWOG (50 bolesnika) ili reduciranoj SWOG shemi (49 bolesnika). Glavne mjere ishoda koje smo uspoređivali bili su tumor-specifična smrtnost, ukupna smrtnost, vrijeme do smrti uzrokovane tumorom, utjecaj karakteristika tumora na tumor-specifičnu i ukupnu smrtnost (broj, stadij, gradus, veličina tumora, recidivni tumor i CIS) te prediktori tumor-specifične i ukupne smrtnosti. Rezultati: Desetogodišnje tumor-specifično preživljenje bolesnika liječenih po SWOG shemi bilo je 94%, dok je u rSWOG skupini iznosilo 96%. Ukupno desetogodišnje preživljenje za SWOG skupinu iznosi 64%, a za rSWOG skupinu 72%. Prosječan vremenski interval do smrti uzrokovane tumorom u SWOG skupini bio je 39± 23 mjeseca, a u rSWOG skupini taj inteval bio je 70± 51 mjeseca. Prosječan vremenski interval za ukupnu smrtnost u SWOG skupini bio je 59± 32 mjeseca, a u rSWOG skupini 77± 34 mjeseca. Ne postoji statistički značajna razlika između stope preživljenja, tumor-specifične smrtnosti i ukupne smrtnosti u dvije promatrane skupine. Zaključak: Reducirana SWOG shema jednako je učinkovita kao i standardizirana SWOG shema za ukupno i tumor-specifično preživljenje bolesnika s mišićnoneinvazivnim karcinomima mokraćnog mjehura.
Abstract (english)
Objectives: The objective of our study was to proof the efficacy of the reduced SWOG (Southwest Oncology Group) scheme in achieving the same overall and tumor-specific survival rate as in the standardized SWOG scheme. Patients and procedures: We performed a historical prospective study of long-term follow-up. Data on patients were obtained by examining the surgical protocols, histopathological findings of the resected tumor tissue and on regular follow-ups till death. Place of research was at the Department of Urology, University Hospital Center Split. The study included 99 patients in the period from January 1 2004 to December 31 2007 who underwent transurethral resection of the non-muscle invasive bladder cancer and received additional intravesical instillation of BCG according to SWOG (50 patients) or reduced SWOG scheme (49 patients). The main outcome measures the comparison of tumor-specific mortality, overall mortality, average survival period, the impact of tumor characteristics on the tumor-specific and overall mortality (number, stage, grade, tumor size, recurrent tumor and CIS) and the predictors tumor-specific and overall mortality. Results: Ten-year tumor-specific survival rate of patients treated according to SWOG scheme is 94%, while in the rSWOG group the survival rate was 96%. Total ten-year survival in the SWOG group is 64%, and 72% in the rSWOG group. Average time period to death caused by tumors in the SWOG group was 39 ± 23 months, and in the rSWOG group that time period was 70 ± 51 months. The average survival period regarding overall mortality in the SWOG group was 59 ± 32 months, and in the rSWOG group 77 ± 34 months. There was no statistically significant difference between the survival rates, tumor-specific mortality and overall mortality in the two groups. Conclusion: The reduced SWOG scheme is as effective as standardized SWOG scheme for the total and tumor-specific survival of patients with non-muscle invasive bladder cancer.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:628751
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2016-10-25 11:08:22